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SUMMARY
A key characteristic of stem cells and cancer cells is their ability to self-renew. To test if Wnt signaling
can regulate the self-renewal of both stem cells and cancer cells in the hematopoietic system, we de-
veloped mice that lack b-catenin in their hematopoietic cells. Here we show that b-catenin-deficient
mice can form HSCs, but that these cells are deficient in long-term growth and maintenance.
Moreover, b-catenin deletion causes a profound reduction in the ability of mice to develop BCR-
ABL-induced chronicmyelogenous leukemia (CML), while allowing progression of acute lymphocytic
leukemia (ALL). These studies demonstrate that Wnt signaling is required for the self-renewal of
normal and neoplastic stem cells in the hematopoietic system.INTRODUCTION
Wnt proteins are secreted signaling molecules that influ-
encebothdevelopmentandcancer. In thecontextof devel-
opment, Wnts regulate segment polarity in Drosophila
(Siegfried and Perrimon, 1994), axis specification in Xeno-
pus (Moon et al., 1997), and differentiation of limbs, brain,
kidney, and the reproductive tract in mice (Liu et al., 1999;
Miller and Sassoon, 1998; Monkley et al., 1996; Parr and
McMahon, 1994; Yoshikawa et al., 1997). In addition to its
importance in normal development, dysregulation of the
Wnt pathway can have potent oncogenic effects. A causal
role for this pathway in oncogenesis was originally demon-
strated usingmice in which overexpression of Wnt-1 led to
mammary tumors (Tsukamoto et al., 1988). In humans, in-
activating mutations in the Wnt pathway inhibitor APC are
associated with the colon cancer susceptibility syndrome
familial adenomatous polyposis (Kinzler et al., 1991).Muta-
tions in APC as well as b-catenin, a key mediator of Wnt
signaling, are also found in a majority of sporadic colon
cancers (Giles et al., 2003), as well as in hepatocellular
carcinoma (Satoh et al., 2000), thyroid cancer, and ovarian
cancer (Gamallo et al., 1999; Garcia-Rostan et al., 1999).528 Cancer Cell 12, 528–541, December 2007 ª2007 ElsevierThe fact that Wnt signaling is dysregulated in multiple
solidcancers togetherwith its observed influenceonhema-
topoietic stem and progenitor cells (reviewed in Reya and
Clevers, 2005) suggests that the same pathway may be-
come aberrantly activated to promote leukemia. Several
studies support this possibility. For example, pre-B cell leu-
kemia lines carrying the E2A-PbX translocation overex-
press Wnt proteins (McWhirter et al., 1999), and survival
of these cells in vitro can be inhibited by blocking Wnt sig-
naling (Mazieres et al., 2005). Similarly, AML-associated
fusion proteins enhance replating efficiency of hematopoi-
etic stemcells (HSCs), and this is abrogatedupon inhibition
of Wnt signaling (Muller-Tidow et al., 2004; Zheng et al.,
2004). Finally, cells from CML patients display activated
Wnt signaling and a dependence on this pathway for
growth in vitro (Jamieson et al., 2004). While these data
suggest that activation of theWnt pathway may contribute
to leukemic cell growth in vitro, whether Wnt signaling is
required for progression of leukemias in vivo is unknown.
To address this question, we generated conditional
b-catenin null mice. Using these mice we show that loss
of b-catenin affects both normal and malignant hemato-
poietic cells in vivo. While HSCs are established in theSIGNIFICANCE
TheWnt pathway has been implicated in the progression of many cancers, but its role in leukemia is unclear. Using
a conditional b-catenin/mouse, we show that in vivo myeloid leukemia progression is dependent on b-catenin.
Importantly, while loss of b-catenin dramatically reduces BCR-ABL-induced CML development, it allows ALL to
proceed unimpaired. Given the evidence that CML may be initiated in HSCs, and ALL in committed precursors,
these data suggest that b-catenin may be preferentially required for leukemias that originate in stem cells.Inc.
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b-Catenin in Normal and CML Stem Cell RenewalFigure 1. Conditional Deletion of b-Catenin in the Hematopoietic System
(A) The schematic indicates the strategy for deletion of b-catenin in hematopoietic cells using mice carrying a floxed b-catenin allele crossed to trans-
genic mice in which expression of the cre recombinase is directed by the vav promoter.
(B) Analysis of deletion efficiency by genomic PCR analysis. Genomic DNA from control and b-catenin/ whole bone marrow cells was amplified
using primer RM68/69, which does not generate a product for the floxed allele but generates a 631 bp product for the floxdel allele (left lanes; 45
relative fluorescence units for / and 0.64 RFU for control), and primer RM41/42/43, which generates a product of 324 bp for the floxed allele
(1.5 RFU for control and 0.0006 RFU for /) and a 500 bp product for the floxdel allele (69 RFU for / and 0.32 for control) (Brault et al., 2001).
Quantitation of the difference in product formation was carried out by real-time PCR analysis. Results are representative of two experiments.
(C) Whole bone marrow lysates from control (+/+) and b-catenin knockout (/) mice were analyzed by western blot for presence of b-catenin.
Results shown are representative of four experiments.
(D) KLS cells were isolated from control (+/+), heterozygous (+/), and conditional b-catenin knockout (/) mice, and RT-PCR analysis was
performed to determine expression of b-catenin. Results are representative of three experiments.absence of b-catenin, they are impaired in long-term
growth andmaintenance following transplantation. Impor-
tantly, using a BCR-ABL model of leukemogenesis, we
show that loss of b-catenin impairs the ability of mice to
develop CML, due in part to decreased self-renewal of
CML stem cells. In contrast, these mice are capable of
developing ALL. Since CML is thought to be initiated in
HSCs, and ALL in committed precursors, these data raise
the intriguing possibility that b-catenin is preferentially re-
quired for BCR-ABL-induced leukemias that originate in
stem cells. These data also suggest that the dependence
of leukemias on Wnt signaling is dictated not only by the
oncogene itself but also by the specific cell that it targets.
RESULTS
Generation of Conditional b-Catenin Null Mice
Conventional b-catenin/mice die in utero (Haegel et al.,
1995; Huelsken et al., 2000). Therefore, to examine the
role of b-catenin in adult hematopoietic stem cell functionCancand leukemia progression, we generated conditional
knockouts. Mice in which b-catenin is flanked by loxP
sites (flox-b-catenin mice) (Brault et al., 2001) were
crossed with mice in which the Cre recombinase is driven
by vav regulatory elements (vav-Cremice). Vav is an adap-
tor protein expressedmostly in the hematopoietic system,
including in HSC-enriched fractions (Almarza et al., 2004;
de Boer et al., 2003). Progeny from this cross would
be expected to delete b-catenin predominantly in the
hematopoietic system (Figure 1A).
To ensure that this strategy was effective, we performed
genomic PCR (Brault et al., 2001). This showed that in
b-catenin/mice (loxp/loxp, cre), the floxed allele was ef-
ficiently deleted and the undeleted allele could no longer
be detected (70- to 2500-fold reduction by real-time
PCR) (Figure 1B). In addition, no b-catenin protein could
be detected in the bone marrow of conditional null mice
(Figure 1C). Finally, b-catenin mRNA expression was un-
detectable in c-kit+LinSca-1+ (KLS) cells, a population
highly enriched for HSCs (Figure 1D). These dataer Cell 12, 528–541, December 2007 ª2007 Elsevier Inc. 529
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b-Catenin in Normal and CML Stem Cell RenewalFigure 2. b-Catenin Is Required for Long-Term Stem Cell Maintenance and Transplantation In Vivo
(A) Bonemarrow cells from control or b-catenin knockout mice were analyzed for frequency of KLSF cells. Dot plots are shown for one representative
control (control, left) and b-catenin knockout mouse (b-catenin/, right).
(B) Average frequency of KLSF cells in control and b-catenin knockout mice. n = 11 for control, n = 13 for knockout.
(C) Five-hundred KLSF cells from control or b-catenin knockout mice were transplanted together with competing bone marrow cells into lethally
irradiated congenic recipients, and donor-derived chimerism was monitored for 20 weeks. Plots show representative donor-derived chimerism
from individual mice at 20 weeks.
(D) Graph of average donor-derived chimerism after long-term reconstitution (5–7 mice in each cohort, p = 0.0079, n = 3). In five independent exper-
iments, the difference in chimerism between control and knockout transplants was 5-fold (500 cells transplanted), 2.8-fold (2000 cells transplanted),
and 1.4-fold (6000 cells transplanted).
(E) Contribution to differentiated lineages from control and b-catenin knockout cells following long-term bone marrow transplantation in peripheral
blood. Results are representative of three independent bone marrow transplantation experiments, with 5–7 mice in each cohort.
(F) Limiting-dilution competitive repopulation analysis of control and b-catenin knockout mice. Eight mice were transplanted at each dose (10, 20, 40,
and 50 cells/recipient for a total of 64 initial recipients for both genotypes). Peripheral blood cells of all surviving recipients were analyzed 10 weeks
after transplantation, and data were analyzed by L-calc software. CRU difference is 4-fold between control and knockout.
(G) Secondary limiting-dilution competitive repopulation analysis of control and b-catenin knockout mice was carried out using the 50 cells/recipient
group of primary transplanted mice at 21 weeks. Whole bone marrow cells were isolated from primary donors and transplanted into 5–7 recipients at
each dose (10,000, 40,000, 80,000, and 160,000 cells/recipient for a total of 48 recipients). Peripheral blood cells of the secondary recipients were
analyzed 10 weeks after transplantation, and data were analyzed by L-calc software. CRU difference is 6.3-fold between control and knockout.
(H) Relative homing ability of control and b-catenin/ bonemarrow cells. A total of 23 106 bone marrow cells from control or b-catenin/mice were
transplanted into irradiated recipients (n = 4 in each group), and the presence of donor-derived cells was analyzed by FACS 6 hr posttransplant. In (B),
(D), (E), and (H), error bars represent SEM.suggested that b-catenin was efficiently deleted in HSCs
and that this model could be used to test the requirement
of b-catenin in HSC renewal and leukemogenesis.
To determine whether loss of b-catenin leads to defects
in HSC function in vivo, we stained for markers of imma-
ture and mature hematopoietic cells. The frequency of
long-term stem cells (c-kit+Lin/loSca-1+Flk2 cells, or
KLSF cells) was equivalent in control and b-catenin/
mice (Figures 2A and 2B). In addition, these cells were
equivalently distributed among the different stages of
the cell cycle (Figure S1 in the Supplemental Data avail-
able with this article online). b-catenin/ mice also had
a normal distribution of B, T, and myeloid cells (data not
shown) as well as CMP, GMP, and CLPs (Figure S2). To530 Cancer Cell 12, 528–541, December 2007 ª2007 Elsevier Itest the long-term self-renewal capacity of HSCs from
b-catenin/ mice, we transplanted 500 KLSF cells from
control and b-catenin/mice in the presence of compet-
ing control bone marrow cells and monitored long-term
reconstitution ability. Mice reconstituted with b-catenin/
KLSF cells displayed a 5-fold reduction in donor chime-
rism compared to mice transplanted with control KLSF
cells (Figures 2C and 2D and Figure S3). Importantly, the
lineage distribution within the control- and knockout-
derived populations was similar (Figure 2E), indicating
that loss of b-catenin does not affect lineage differentia-
tion, but rather impairs long term-growth and mainte-
nance of HSCs. In addition, we carried out competitive
limiting-dilution experiments using a range of 10–50 cellsnc.
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b-Catenin in Normal and CML Stem Cell Renewalper recipient and found a 4-fold reduction in the frequency
of functional HSCs as determined by CRU analysis
(Figure 2F and Figure S4A). Upon secondary transplants
there was a 6.3-fold reduction in the frequency of
functional HSCs in b-catenin-deficient bone marrow
(Figure 2G and Figure S4B), supporting the conclusion
that the defect was in long-term HSC self-renewal. Finally,
at short time points after transplantation(Adams et al.,
2006), the levels of chimerismwere equivalent (Figure 2H),
suggesting that the long-term HSC renewal defects
observed were unlikely to be a consequence of impaired
homing.
Loss ofb-Catenin Leads toAlteredCharacteristics
of Leukemia Progression In Vivo
The influence of b-catenin on HSC function and the many
parallels between the regulation of stem cells and cancer
cells (Beachy et al., 2004; Reya et al., 2001; Wu et al.,
2007) suggested that b-catenin may also affect leukemia
formation. To test this we utilized a mousemodel of leuke-
mogenesis involving the BCR-ABL fusion protein. In
humans, translocations involving the BCR and ABL genes
lead to both CML and ALL (Ren, 2005). This disease can
be recapitulated in mice by retrovirally introducing the
p210 form of BCR-ABL into hematopoietic progenitors
and transplanting these cells into lethally irradiated mice
(Daley et al., 1990; Pear et al., 1998; Witte, 2001). We
used this model to test the requirement of b-catenin in
leukemia progression.
c-kit-enriched bone marrow cells from control or
b-catenin/ mice were infected with control retroviruses
or viruses carryingBCR-ABL and transplanted (Figure 3A).
Forty-eight hours after infection, control and b-catenin/
cells expressed BCR-ABL transcripts (Figure 3B). In addi-
tion, the frequency of infected cells was similar in control
and knockout cultures as determined by an IRES-GFP
marker carried by the virus (data not shown). Mice trans-
planted with control BCR-ABL-infected cells became
sick 20–24 days after transplantation (Figure 3C). In con-
trast, mice transplanted with b-catenin/ BCR-ABL-
infected cells showed a significant delay in onset of
disease (75 days versus 46 days; Figures 3C and 5C).
We first analyzed the leukemias induced by BCR-ABL-
infected control cells and found that a majority of them
resembled CML. These leukemias were associated with
weight loss, lung hemorrhaging, and significant spleno-
megaly (Figure 3E) compared to vector-infected controls
(Figure 3D). Closer histological examination revealed that
the lung and the liver were extensively infiltrated with leu-
kemic cells, consistent with CML-like disease (Figure 4,
top and middle rows; black arrowheads indicate leukemic
cells).
Mice transplanted with BCR-ABL-infected b-catenin/
cells displayed a markedly different course of disease.
Several displayed paralysis of the hind legs, indicative of
tumors in the spinal cord (Figure 3F, left). These mice did
not display the lung hemorrhaging nor the extent of
splenomegaly observed with BCR-ABL-infected control
transplants (Figure 3F, middle and right panels), andCanthey lacked the extensive infiltration of the lungs and liver
(Figure 4, bottom row).
Loss of b-Catenin Impairs In Vivo Progression
of CML but Allows Normal Development of ALL
To determine the identity of the leukemic cells in mice
transplanted with BCR-ABL-infected control and knock-
out cells, we carried out histological analysis of the spleen.
This revealed extensive infiltration of both immature and
mature granulocytes in control transplanted mice (Fig-
ure 5A, middle). In contrast, the majority of mice trans-
planted with BCR-ABL-infected b-catenin/ cells dis-
played lymphocytic cell infiltrates (Figure 5A, right).
FACSanalysis confirmed that themajority of leukemic cells
in control micewere granulocytes (Figure 5B, upper panel);
in contrast, b-catenin/ transplanted mice showed a sig-
nificant expansion of B cells (Figure 5B, lower panels)
that were IgM (data not shown), indicating that the leuke-
mia resembled pre-B-ALL. Cumulative analysis of four
independent groups of transplants revealed that the ma-
jority of mice (82.6%, 19/23) transplanted with BCR-
ABL-infected control cells displayed a CML-like disease
and only a fewmice (17.4%, 4/23) succumbed to ALL (Fig-
ure 5C, bottom row). In contrast only 19% (4/21) of mice
transplanted with BCR-ABL-infected b-catenin/ cells
succumbed to CML (Figure 5C, top row; Figure 5D). Im-
portantly, at early time points the level of chimerism of
BCR-ABL-infected control and b-catenin null cells was
equivalent, suggesting that the reduced frequency of
CML was unlikely to be due to a homing or engraftment
defect (Figure S5). The frequency of BCR-ABL-positive
clones with unique integration sites was also similar in
the BCR-ABL-infected control or b-catenin null cells, sug-
gesting that an early defect in the presence of leukemia-
initiating clones was unlikely (Figure S6A). Furthermore
the leukemias that did fully form in both control and b-cat-
enin null samples appeared to be oligoclonal, suggesting
that an insertional mutagenesis event, which can some-
times act to cooperatively lead to oncogenesis, was un-
likely to be the basis of the observed CMLs (Figure S6B).
Interestingly, the absence of b-catenin did not hinder
the progression to ALL, which in the absence of CML
became the predominant disease in 81% (17/21) (Fig-
ures 5C and 5D) of the mice transplanted with BCR-
ABL-infected knockout cells. Further, the ALLs could be
serially transplanted, confirming that they had intact re-
newal capacity in vivo (Figures S7A–S7C). b-catenin ex-
pression was undetectable in leukemias from b-catenin
null cells (Figures S8A–S8C), making it unlikely that they
were progressing normally because of not having deleted
b-catenin. These data cumulatively indicate a differential
requirement for b-catenin in BCR-ABL-induced CML
and ALL.
Loss of b-Catenin Impairs Self-Renewal of CML
Stem Cells
We next investigated the cellular basis for the impaired
ability of b-catenin/ cells to allow CML progression
in vivo. To test whether knockout cells displayedcer Cell 12, 528–541, December 2007 ª2007 Elsevier Inc. 531
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b-Catenin in Normal and CML Stem Cell RenewalFigure 3. Loss of b-Catenin Leads to Altered Characteristics of Leukemia Progression In Vivo
(A) Experimental strategy to model BCR-ABL-induced leukemia. c-kit-enriched cells were isolated from control or b-catenin knockout mice and
infectedwithBCR-ABL retroviruses for 48 hr prior to transplantation of 2–53 105 cells into lethally irradiated recipient mice. LTR, long terminal repeat.
(B) Control and b-catenin knockout c-kit-enriched bone marrow cells were infected with either vector control or BCR-ABL retroviruses, and expres-
sion levels of BCR-ABL were analyzed by real-time PCR. Results were normalized to the housekeeping gene b-actin. Data are an average of five
independent samples. Error bars represent SEM.
(C) Survival curve of mice receiving BCR-ABL-infected control (+/+) or b-catenin knockout (/) c-kit-enriched bone marrow cells. Data shown are
from one of four independent experiments, with 7–9 mice in each experimental group per experiment.
(D–F) Gross examination of mice transplanted with vector-infected control, BCR-ABL-infected control, and b-catenin knockout cells. A majority of
mice transplanted with BCR-ABL-infected control cells became weak but did not develop paralysis, unlike several of those transplanted with knock-
out cells (left panel). Appearance of lung inmice transplantedwith vector-infected control,BCR-ABL-infected control, orBCR-ABL-infected knockout
cells (middle panel). Relative splenomegaly of mice transplanted with vector-infected control, BCR-ABL-infected control, or b-catenin knockout cells
(right).decreased survival following BCR-ABL infection, control
and b-catenin/ c-kit-enriched cells were infected with
control vector or BCR-ABL, and survival analyzed
(Figure 6A). BCR-ABL led to increased survival equiva-
lently in both the control and b-catenin/ cells
(Figure 6B). To test whether the loss of b-catenin could
lead to reduced CML formation by reducing long-term
propagation of cancer cells, we first carried out a serial re-
plating assay, which provides an indication of cancer cell532 Cancer Cell 12, 528–541, December 2007 ª2007 Elsevier Inself-renewal in vitro. Both control and knockout cells
formed equal numbers of colonies following vector and
BCR-ABL infection in the first plating (Figures 6C and
6D). By the second plating, the BCR-ABL-infected control
cells had an increased ability to give rise to new colonies
as compared to vector-infected cells (Figure 6C). In con-
trast, the ability of BCR-ABL to induce colony formation
was reduced to control levels in the absence of b-catenin
(Figure 6D). Further, the control BCR-ABL cells continuedc.
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b-Catenin in Normal and CML Stem Cell RenewalFigure 4. Loss of b-Catenin Leads to an Altered Pattern of Leukemic Cell Infiltration in the Lung and Liver
Hematoxylin/eosin staining of tissue sections from lung (left panels) and liver (right panels) of mice transplanted with vector-infected control,
BCR-ABL-infected control, or BCR-ABL-infected knockout cells. Arrowheads point to infiltration of leukemic cells into tissues. Mice transplanted
with BCR-ABL-infected b-catenin knockout cells show either reduced infiltration (bottom row left [lung], black arrowhead) or a different pattern of
infiltration (bottom row right [liver], black arrowhead). The scale bar represents 100 mm.to generate more colonies than control vector-infected
cells in the third (2.5-fold) and fourth platings (3.4-fold)
(Figure 6C). Interestingly, by the third plating, there ap-
peared to be colonies in the knockout cultures infected
with BCR-ABL as well (Figure 6D); however, these colo-
nies were morphologically different from the myeloid col-
onies in the control cultures and were composed primarily
of B cells (Figure 6E). This result mirrored the in vivo finding
that the b-catenin/ cells can be transformed along the B
lineage and suggested that b-catenin is critically needed
for the increased self-renewal capacity bestowed by
BCR-ABL on hematopoietic stem cells to allow transfor-
mation to occur along the myeloid lineage.
Tomore definitively test whether the CML impairment in
the absence of b-catenin was due to a defect in cancer
stem cell self-renewal in vivo, we isolated GFP+KLS cells
from control or b-catenin/ primary CML and trans-
planted them into secondary recipients. These cells have
been shown previously to successfully propagate CML
formation (Hu et al., 2006), thus broadly fitting the criteriaCanfor CML stem cells. Upon transplantation, CML stem cells
from control mice successfully propagated leukemia such
that 65% of the recipients succumbed to the disease
(Figure 6F). In contrast, none of the recipients transplanted
with CML stem cells from the b-catenin/ mice devel-
oped the disease during the same time period. These
data are consistent with the in vitro replating data and in-
dicate that the loss of b-catenin impairs CML progression
by reducing the self-renewal ability of CML stem cells.
We also carried out control experiments to rule out the
possibility that the impaired CML progression was due to
an altered frequency of cells that could serve as targets
forBCR-ABL. FACS analysis revealed equivalent fractions
of lineage-negative, long-term and short-term cells in both
the control and b-catenin knockout c-kit+ population
(Figures S9A–S9C). We also found that control and b-cat-
enin knockout cells retained similar frequencies of lym-
phoid and myeloid lineage-committed cells following in-
fection withBCR-ABL (Figure S9D). Further, when purified
KLSF cells were used to equalize the target populationcer Cell 12, 528–541, December 2007 ª2007 Elsevier Inc. 533
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b-Catenin in Normal and CML Stem Cell RenewalFigure 5. Loss of b-Catenin Impairs In Vivo Progression of CML but Allows Normal Development of ALL
(A) Histologic appearance of leukemic cells in spleens of the majority of mice transplanted with BCR-ABL-infected control and b-catenin knockout
cells. Arrowheads point to an increased frequency of immature and mature granulocytic cells in the spleens of mice transplanted with BCR-ABL-
infected control cells, and increased lymphocytic cells in the spleens of mice transplanted with BCR-ABL-infected b-catenin knockout cells. Scale
bar represents 100 mm.
(B) Bone marrow cells from mice receiving BCR-ABL-infected control or b-catenin knockout cells were analyzed by flow cytometry for increased
presence of granulocytic (Mac-1+Gr-1+ cells shown in upper panels) or lymphocytic lineages (B220+ cells shown in lower panels).
(C) Cumulative data from four experiments indicating type of leukemia induced by BCR-ABL in mice transplanted with control or b-catenin knockout
(/) cells. Each circle represents an individual mouse. CML, chronic myelogenous leukemia; ALL-B, B cell acute lymphocytic leukemia; ALL-T, T cell
acute lymphoblastic leukemia.
(D) Distribution of CML and ALL induced by BCR-ABL when using control or b-catenin knockout c-kit-enriched cells. *p = 0.005 (t test from four
experimental groups).534 Cancer Cell 12, 528–541, December 2007 ª2007 Elsevier Inc.
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b-Catenin in Normal and CML Stem Cell Renewalfor BCR-ABL infection (Figure S9E), control cells gave rise
to leukemia in 100% of the mice (CML in 7/8 and B-ALL in
1/8), while knockout cells generated significantly fewer
CMLs (12.5%, only one case of CML). Finally, reintroduc-
tion of activated b-catenin complemented the defect in
CML formation (Figures S10A–S10C). These data cumula-
tively indicate that the reducedability ofBCR-ABL to cause
CML in the absence of b-catenin is unlikely to be due to dif-
ferences in target populations infected between wild-type
and mutant mice.
Differential Wnt Reporter Activity
in BCR-ABL-Induced CML and ALL
We next investigated whether the differential dependence
of CML versus ALL on b-catenin was due to differential uti-
lization of the Wnt pathway in the two leukemias. We thus
generated a lentiviral Wnt reporter, BATRED (see Experi-
mental Procedures), that would fluoresce red upon activa-
tion of a Wnt signal and could be detected in the GFP-
expressing BCR-ABL-infected leukemia cells. In control
experiments, theBATRED reporter responded to b-catenin
activation as expected (Figure S11). Reporter activity
could be detected in 42% (188/448) of the CML cells iso-
lated from control mice (Figure 7A). In some CML samples
the reporter activity was particularly high in some cells and
mid to low in other cells, but consistently above back-
ground control levels. In contrast, BATRED activity was
undetectable or significantly lower in the cells derived
from ALL samples (Figure 7A). As a control, we confirmed
that theBATRED reporter had integrated into both ALL and
CML cells (Figure 7B). Additionally, the BATRED reporter
could be activated in ALL cells when Wnt signaling was
forcibly turned on using lithium chloride (Figure 7C), sug-
gesting it was unlikely that the reporter was silenced pref-
erentially in ALL cells. These data indicate that Wnt
reporter activity is higher in BCR-ABL-induced CML com-
pared to ALL. This differential utilization is consistent with
the differential requirement for b-catenin in CML and ALL.
BCR-ABL-Induced Phosphorylation Is Reduced
in the Absence of b-Catenin
Finally, we investigated the specific molecular changes
that occur with the loss of b-catenin that may contribute
to the impaired ability ofBCR-ABL to transform cells along
the myeloid lineage. We first examined whether the b-
catenin/ cells have reduced levels of genes that confer
myeloid identity but did not find any changes in the ex-
pression of CEBPalpha, Id1, or Pax5 (Figure S12). Lack
of b-catenin also did not significantly change the expres-
sion of cyclinD1, cyclinD2, and c-Myb (data not shown).
It has previously been shown that CML progression, but
not ALL progression, is impaired in the absence of Stat5a
(Ye et al., 2006; Sexl et al., 2000), which is normally phos-
phorylated and thereby activated by BCR-ABL. We thus
tested if phosphorylated Stat5a was reduced in the
absence of b-catenin, and found that p-Stat5a was re-
duced by approximately 4-fold in the b-catenin null cells
following BCR-ABL transduction (Figures 8A and 8B).
While there was some reduction in total Stat5 protein asCanwell, it was not as marked as the reduction in phosphory-
lated Stat5 and did not appear to be responsible for the re-
duced levels of p-Stat5a observed (Figures 8C and 8D).
That the loss of Stat5a leads to a differential impact on
CML and ALL together with our data that loss of b-catenin
reduces BCR-ABL induced p-Stat5a provides support, at
amolecular level, for the idea that b-catenin is differentially
required in CML and ALL. In addition to the phosphoryla-
tion defect of Stat5a, we also observed a global decrease
in protein tyrosine phosphorylation in established CML,
but not ALL, derived from b-catenin/ cells (2.6- to 4-
fold reduction; Figure 8E). While the transcriptional levels
of BCR-ABL were relatively equivalent in the leukemias
from control and b-catenin/ cells (Figure 8F), the levels
of BCR-ABL protein was significantly reduced in the ab-
sence of b-catenin in CML cells but not ALL cells (Fig-
ure 8G). In light of the fact that BCR-ABL and b-catenin
can form a complex in vivo (Coluccia et al., 2007; and
data not shown), our data raise the intriguing possibility
that the loss of b-catenin leads to reduced levels of
BCR-ABL and reduced phosphorylation of relevant sub-
strates; this reduced activation of downstream targets
may lead to a consequent decrease in CML self-renewal
ability and progression.
DISCUSSION
Our studies indicate that deletion of b-catenin in the hema-
topoietic system impairs normal HSC function and leuke-
mia progression in vivo. During normal hematopoiesis,
while the loss of b-catenin did not affect the initial estab-
lishment of HSCs and hematopoietic differentiation, it
led to a clear reduction of long-term maintenance as
assayed by transplantation. These data overall strengthen
the findings that retroviral modulation of Wnt signaling in
HSCs can influence proliferation and reconstitution in
mice (Reya et al., 2003; Willert et al., 2003; Baba et al.,
2005, 2006) as well as the observation that delivery of
Wnt protein can enhance human HSC reconstitution in
a xenograft model (Murdoch et al., 2003). However, an
IFN-inducible b-catenin/ mouse was reported to have
no defects in the hematolymphoid or any other system
(Cobas et al., 2004). It is possible that the differences in
phenotypes observed may be due to the approach by
which b-catenin was deleted. Using IFN induction to in-
duce deletion in adulthood may set up a different context
for testing requirements than using a transgenic in which
cre recombinase is driven by a promoter starting in embry-
onic life, as was done in our case as well as in experiments
demonstrating a requirement for b-catenin in develop-
ment of multiple major organs (Brault et al., 2001; Catte-
lino et al., 2003; Dessimoz et al., 2005; Xu et al., 2003).
One of themost important findings that we report here is
that loss of b-catenin affects myeloid leukemia progres-
sion in vivo. Several studies have suggested that Wnt sig-
naling is active in many leukemic cell lines and patient
samples (reviewed in Reya and Clevers, 2005). However,
whether this pathway is required for in vivo leukemia pro-
gression was unknown. Our data clearly demonstrate thatcer Cell 12, 528–541, December 2007 ª2007 Elsevier Inc. 535
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b-Catenin in Normal and CML Stem Cell RenewalFigure 6. Loss of b-Catenin Impairs BCR-ABL-Induced Renewal of CML Stem Cells
(A) A schematic of the strategy to determine relative survival and replating efficiency after BCR-ABL infection in control and b-catenin knockout cells.
(B) c-kit-enriched cells from control or b-catenin knockout mice were infected with vector or BCR-ABL and stained with annexin-V and 7-AAD.
Annexin-V+7-AAD cells were quantified to determine frequency of apoptotic cells. Results are representative of four independent samples.536 Cancer Cell 12, 528–541, December 2007 ª2007 Elsevier Inc.
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b-Catenin in Normal and CML Stem Cell RenewalFigure 7. Differential Wnt Reporter
Activity in CML versus ALL
(A) Leukemic cells from BCR-ABL-induced
CML or ALL were sorted for GFP and then in-
fected with a lentiviral Wnt reporter expressing
dsREd (BATRED) upon Wnt activation. Cyto-
spins were prepared 48 hr later and observed
by immunofluorescence microscopy.
(B) Genomic DNA was extracted from Wnt-re-
porter-infected CMLor ALL cells, and viral inte-
gration was checked by PCR analysis using
specific primers designed to amplify dsREd.
The Wnt reporter plasmid served as a positive
control. Data shown in both (A) and (B) are rep-
resentative of three independent experiments.
(C) GFP+ leukemic cells from b-catenin/ ALL
were sorted, infected with the BATRED re-
porter virus, and treated with control media or
1 mM lithium chloride for 48 hr. Cells were
then cytospun, and reporter activity was ana-
lyzed by immunofluorescence. Data are repre-
sentative of two independent experiments.
In (A) and (C), the scale bar represents 10 mm
and 3 mm, respectively.deletion of b-catenin leads to a reduced ability of BCR-
ABL to induce CML in vivo. Further we found that the
impaired CML incidence could be rescued by ectopic
b-catenin expression (Figure S10), supporting the notion
that the loss of b-catenin directly impacts CML progres-
sion. Interestingly, only a low dose of b-catenin was effec-
tive in this rescue, while a high dose appeared to interfere
with leukemogenesis. These data indicate that the precise
levels of b-catenin are critical to determining its influence
on hematopoietic cells, and they may help explain the
data observed with transgenic mice overexpressing high
levels of b-catenin in which an expansion of phenotypic
HSCs is followed by loss of differentiated hematopoietic
cells (Kirstetter et al., 2006; Scheller et al., 2006).
Our data also provide insight into the cellular andmolec-
ular basis for impaired CML progression in the absence of
b-catenin. At a cellular level, the serial replating and CML
serial transplantation assays suggest that the decreased
progression of CML is due to a reduced ability of BCR-
ABL to sustain long-term renewal of CML stem cells in
the absence of b-catenin. At a molecular level, our data
show that the loss of b-catenin reduces the levels of
BCR-ABL and impairs phosphorylation of proteins in
BCR-ABL-inducedCML. The fact that the loss ofb-cateninCanreduces phosphorylation of Stat5a and other substrates
raises the possibility that Wnt signaling may regulate
CML progression by allowing the maintenance of normal
levels of BCR-ABL protein, which in turn phosphorylates
Stat5a and other substrates needed for optimal transfor-
mation along the myeloid lineage.
Remarkably, while CML formation was reduced in the
absence of b-catenin, ALL formation could proceed rela-
tively unimpaired. It has been proposed that CML and
ALL may arise from distinct cells of origin. Specifically,
some data indicate that the cell of origin for CML is
a stem cell (Li et al., 1999; Takahashi et al., 1998), while
the cell of origin for ALL is a committed B cell precursor
(Li et al., 1999). In our experiments presented here, we
find that CML occurs almost exclusively when KLSF cells
are used as the cell of origin (Figure S9). Furthermore, we
find that when progenitor B220+IgM cells are used as the
cell of origin, the leukemias that are generated are B-ALL
(Figure S13). These data indicate that CML is the predom-
inant disease when starting with an uncommitted HSC-
enriched fraction and that B-ALL is predominant when
committed lymphoid progenitor cells are targeted. The
fact that we do not observe significant ALL from BCR-
ABL-infected HSCs suggests that the cells in which(C and D) Long-term serial replating. c-kit-enriched control or b-catenin/ cells were infected with vector or BCR-ABL, and 5000 GFP-positive cells
were sorted into wells containingmethylcellulose media to assess primary colony formation. Colony numbers were counted on days 8–10. Cells were
then harvested and counted, and 5000 cells were replated for a second, third, and fourth time, and colonies were counted on days 8–10 after each
replating. White bars represent B lineage colonies. Results shown are an average of three independent experiments. Error bars show SEM.
(E) BCR-ABL-infected control and b-catenin/ colonies were collected after the third and fourth plating and stained with the B cell marker B220. The
plot shown is a representative FACS from the fourth plating.
(F) In vivo self-renewal assay for CML stem cells. Irradiated recipient mice were transplanted with 10,000 KLSGFP+ cells (CML stem cells) sorted from
control or b-catenin knockout CMLs. Survival curves show the frequency of recipients succumbing to disease after receiving KLS cells fromwild-type
CML (solid line) or b-catenin null CML (dashed line) stem cells (total number of mice transplanted = 12). In (B), (C), and (D), error bars represent SEM.cer Cell 12, 528–541, December 2007 ª2007 Elsevier Inc. 537
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b-Catenin in Normal and CML Stem Cell RenewalFigure 8. BCR-ABL-Induced Phosphorylation of Stat5a Is Reduced in the Absence of b-Catenin
(A and C) c-kit enriched control or b-catenin/ cells were infected with BCR-ABL for 48 hr. Infected cells (GFP positive) were sorted and cultured for
another 3–4 days, and then cytospins were prepared and stained with indicated antibodies. Data are representative of three independent experi-
ments. In (A) and (C), the scale bar represents 10 mm. (B and D) Quantification of fluorescence intensities/cell for phosphorylated (B) and total Stat5a
(D) using Metamorph software. In control cells, phosphorylation of Stat5a was significantly induced following BCR-ABL transduction (p = 0.003). In
contrast, BCR-ABL transduction in b-catenin/ cells did not induce Stat5a phosphorylation over vector and showed reduced phosphorylation com-
pared to BCR-ABL-infected control cells (p = 0.008). (E) Relative levels of protein tyrosine phosphorylation in CML and ALL cells from control or
b-catenin/ leukemias. GFP+ leukemia cells from CML or ALL of each genotype were sorted, and protein lysates were analyzed by western blotting
with an anti-phosphotyrosine antibody. (F) Real-time PCR analysis of BCR-ABLmRNA levels in control and b-catenin/ leukemia cells. (G) Relative
levels of BCR-ABL protein in CML and ALL from control or b-catenin/ leukemias. GFP+ leukemia cells from CML or ALL of each genotype were
sorted, and protein lysate was analyzed by western blotting with an anti-abl antibody. Data are representative of two to three independent experi-
ments. In (B), (D), and (F), error bars represent SEM.the leukemia initiates may determine the outcome of the
leukemia subtype. This is similar to patients in whom the
BCR-ABL translocation can be found in multiple lineages
(suggesting a stem cell hit) but only CML occurs. Thus it is
possible that the requirement for b-catenin is different in
the two leukemias precisely because of the different tran-
scriptional contexts in the two different cells of origin. If538 Cancer Cell 12, 528–541, December 2007 ª2007 Elsevier Ithis is the case, the low frequency of B-ALL from KLSF
may indicate a low level of contamination of progenitors
in the KLSF fractions or some level of differentiation during
theBCR-ABL infection process in vitro. On the other hand,
the fact that we do observe some frequency of B-ALL
even when starting with KLSF cells may indicate that
ALL can be initiated in either uncommitted or committednc.
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ential need for b-catenin is not because the initiating cell is
different for CML and ALL but because the leukemias are
ultimately propagated along different lineages, which
have different transcriptional contexts.
Several genetic changes have been shown to lead to
altered ratios of CML and ALL. For example, the combined
loss of the src kinases Lyn, Hck, and Fgr preferentially
reduces the incidence of B-ALL relative to CML (Hu
et al., 2004), while reduced activity of the tumor suppres-
sor Arf preferentially accelerates ALL formation (Williams
et al., 2006). Insight into the molecular changes that lead
to a preferential reduction of CML incidence has come pri-
marily from studies of mutations of the abl kinase domain.
Specifically, mutations in the SH2 domain as well as in the
Grb2-binding domain of BCR-ABL lead to reduced forma-
tion of CML but allow normal progression of ALL (Million
and Van Etten, 2000; Roumiantsev et al., 2001). However,
downstream pathways or cascades that may mediate the
differential effects of these mutations remain less well elu-
cidated. This raises the possibility that these mutations
may affect the ability of BCR-ABL to influence the Wnt
pathway. Alternatively, Wnt signaling may be an indepen-
dent modulator of the differential signaling requirements
between CML and ALL progression.
Overall, our work supports data showing that Wnt
signaling is active in and important for humanCML. Specif-
ically it has been shown that granulocyte-macrophage pro-
genitors from chronic myelogenous leukemia patients and
blast crisis cells from patients resistant to therapy display
activated Wnt signaling (Jamieson et al., 2004). Addition-
ally, inhibition of b-catenin through ectopic expression of
axin decreases the replating capacity of leukemic cells,
suggesting that human chronic myelogenous leukemia
precursors are dependent on Wnt signaling for growth
and renewal in vitro. Our data using a mouse model of
BCR-ABL-induced CML are consistent with these findings
and demonstrate that progression of CML in vivo is also
critically dependant on intact b-catenin. The work in the
human system together with that in our mouse model
collectively suggests thatWnt signaling could prove to be a
relevant therapeutic target. Thus, in the long-term, it will be
important to explore whether blocking Wnt signaling either
alone or togetherwith inhibition ofBCR-ABL kinase activity
may be an effective avenue to halt CML progression.
EXPERIMENTAL PROCEDURES
Mice
The loxP-b-catenin and Vav-cre transgenic mice used were in the
C57Bl/6J background. Transplant recipients (C57Bl/Ka CD45.1)
were 8–10 weeks of age. All mice were bred and maintained on acid-
ified water in the animal care facility at Duke University Medical Center.
All animal experiments were performed according to protocols
approved by the Duke University Institutional Animal Care and Use
Committee.
HSC Isolation and Analysis
Isolation of HSCs from bone marrow and their transplantation for
in vivo analysis of function were performed as described (Domen
et al., 2000; Duncan et al., 2005). For the competitive repopulationCanunit (CRU) assay, 10, 40, and 50 sorted KLSCD34 control or
b-catenin/ bone marrow cells were mixed with 200,000 competing
bone marrow cells and injected into lethally irradiated CD45.1 recipi-
ents. Multilineage repopulation was assessed at 10 weeks after trans-
plantation. Secondary limiting-dilution competitive repopulation anal-
ysis was carried out as described (Ema et al., 2005). Whole bone
marrow cells were isolated from primary recipients originally trans-
planted with control or b-catenin/ KLSCD34 cells for 21 weeks
and transplanted into 5–7 recipients at each dose for each genotype
(10,000, 40,000, 80,000, and 160,000 cells/recipient). Peripheral blood
cells of the secondary recipients were analyzed 10 weeks after trans-
plantation. CRU was calculated using L-Cal software (StemCell Tech-
nologies). To assess homing in vivo, 2 3 106 bone marrow cells from
control or b-catenin/ mice were transplanted into lethally irradiated
45.1 recipients (4 mice/group). The recipient mice were sacrificed 6 hr
posttransplantation, and the presence of donor cells was analyzed by
FACS. For leukemia stem cell self-renewal analysis in vivo, CML stem
cells were isolated from CMLs of each genotype as described before
(Hu et al., 2006). To retrieve sufficient numbers of CML stem cells
(from pooled leukemias) to cause secondary disease, the primary
CML was induced with high numbers of KLSF cells (50,000 at 50%
transduction efficiency). Ten thousand freshly isolated CML stem cells
were transplanted into lethally irradiated recipient mice together with
200,000 competitive whole bone marrow cells (n = 6 per group).
Construction and Use of Lentiviral Wnt Reporter
To construct a lentiviral Wnt reporter that would fluoresce red upon
activation of the Wnt signal, we used the reporter elements of the
BATGAL construct in which seven tandem Lef/Tcf sites were cloned
upstream of the minimal promoter TATA box of the Siamois gene
(Maretto et al., 2003). These ‘‘BAT’’ elements were cloned in front of
a ds‘‘RED’’.T4 element (Bevis and Glick, 2002). Second, the XmaI and
BsrG1 fragment of lenti-OT-GFP (Reya et al., 2003) was replaced
by the seven tandem Lef/Tcf sites, minimal promoter TATA, and
dsRED.T4, resulting in the ‘‘BATRED’’ reporter. For detecting Wnt sig-
naling by dsREd lentiviral Wnt reporter, GFP-positive leukemia cells
from CML or ALL mice were sorted and infected with lentiviral
reporter for 48 hr, and cytospins were generated. Confocal images
were obtained with a Zeiss 410 Axiovert Microscope.
Analysis of Diseased Mice
After transplantation, recipient mice were evaluated daily for signs of
morbidity, weight loss, failure to thrive, and splenomegaly. Premorbid
animals were sacrificed and relevant tissues harvested and analyzed
by flow cytometry and histopathology. For flow cytometric analysis,
leukemic cell populations were incubated with antibodies to murine
CD3, B220, Gr-1, and Mac-1 (eBiosciences) and analyzed on FAC-
Vantage SE (BD) with FlowJo software (Tree Star, Inc). Mice that
died prior to analysis (three in the control group, and one in the /
group) were excluded from Figure 4C.
Cell Culture and Methylcellulose Colony Formation
For liquid culture, control or BCR-ABL-infected c-kit-enriched cells
were sorted directly into 96-well U bottom plate with the samemedium
used for prestimulation of cells (Supplemental Experimental Proce-
dures); for methylcellulose assays, 1000–5000 GFP-positive cells
were sorted directly into 12-well plates with complete methylcellulose
medium (StemCell Technologies, catalog number M3434). Colony
numbers were initially counted 8–10 days after plating. Subsequently,
cells were harvested and counted, and 1000–5000 cells were replated
into new 12-well plates. Apoptosis assays were performed by staining
cells with annexin-V and 7-AAD (BD, Biosciences).
Immunofluorescence Staining
Vector or BCR-ABL-infected c-kit-enriched cells were sorted for GFP
by FACS and cytospun, and fixed in 4% paraformaldehyde. Primary
antibodies used were goat anti-phosphorylated Stat5a (sc-11761,
Santa Cruz) or rabbit anti-Stat5a (sc-1081, Santa Cruz), and secondarycer Cell 12, 528–541, December 2007 ª2007 Elsevier Inc. 539
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b-Catenin in Normal and CML Stem Cell Renewalantibodies were rabbit anti-goat-PE or donkey anti-rabbit-PE. DAPI
(Molecular Probes) was added as a nuclear counter-stain.
Supplemental Data
The Supplemental Data include Supplemental Experimental Proce-
dures and thirteen supplemental figures and can be found with
this article online at http://www.cancercell.org/cgi/content/full/12/6/
528/DC1/.
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